Quick Take
Akouos (AKUS) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing genetic treatments for hearing loss.
AKUS won’t enter trials for its lead candidate until 2021, with initial data readout not until 2022, so the IPO is likely more suited to institutional investors.
I’ll provide an update when we learn more about the IPO from management.
Company & Technology
Boston, Massachusetts-based Akouos was founded to create a precision genetic medicine platform to develop AAV-delivered gene therapies for